OligoEngine

OligoEngine appears to be a Seattle-based RNAi-focused biotechnology company operating historically under the OligoEngine name and more recently under Halo-Bio RNAi Therapeutics. The company develops RNAi research tools, oligo design and synthesis capabilities, and a therapeutic platform centered on multivalent RNA constructs for multi-gene suppression. Its platform includes MV-RNA, an RNA CORE nanoparticle architecture, and programmable particle shell technologies intended to improve delivery of RNAi therapeutics. Publicly available materials position the company as both a research platform provider and an early-stage therapeutic developer targeting cancer and infectious diseases. No evidence of approved products or clinical-stage assets was identified, so the company is best characterized as preclinical.